ArticleiScience2026
F-53B exposure accelerates progression from preexisting fatty liver to non-alcoholic steatohepatitis and hepatic fibrosis.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
6:2 Chlorinated polyfluoroalkyl ether sulfonate (F-53B) is prevalent in the environment, yet its effect on pre-existing metabolic dysfunction-associated steatotic liver disease (MASLD) remains unclear. Using adult male zebrafish with high-fat diet-induced MASLD, we investigated the hepatotoxicity of F-53B. Following exposure, F-53B exacerbated hepatic damage in MASLD zebrafish, accelerating progression to metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis. Notably, environmentally relevant concentrations altered lipid metabolism and MASH/fibrosis markers only in MASLD fish, while high concentrations were required to affect normal-diet fish. This heightened susceptibility stemmed from increased hepatic F-53B accumulation in diseased livers. Mechanistically, liver-type fatty acid-binding protein (L-FABP) knockdown in HepG2 cells reduced lipid accumulation, inflammatory and fibrotic responses, identifying L-FABP as a key F-53B transporter. These findings demonstrate that metabolic dysfunction increases vulnerability to F-53B hepatotoxicity, highlighting the need to consider pre-existing conditions in environmental pollutant risk assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.